Company news
Immuneering Corporation news in 2022
Immuneering Corporation's news releases, calls and decks from 2022, newest first.
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
November 27, 2022
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 9, 2022
Immuneering Announces Participation in November Investor Conferences
November 2, 2022
Immuneering Appoints Leah R. Neufeld as Chief People Officer
October 19, 2022
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
September 29, 2022
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
September 1, 2022
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 9, 2022
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104
May 25, 2022
Immuneering Announces Participation in Upcoming Investor Conferences
May 19, 2022
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 9, 2022
Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
March 9, 2022
Immuneering Announces Participation in March Investor Conferences
February 23, 2022
Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.
January 17, 2022
Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event
January 5, 2022
Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management
January 2, 2022